Sellas Life Sciences Group
SLS · United States
Share price · SLS
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when SLS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 17 Nov 2026+156.4%
- 28 Oct 2026-14.7%
- 20 Oct 2026+14.2%
Nothing announced by SLS that day or the session before.
- 11 Sep 2026-14.4%
Nothing announced by SLS that day or the session before.
- 21 Aug 2026+15.4%
Nothing announced by SLS that day or the session before.
- 29 Jun 2026+24.7%
Nothing announced by SLS that day or the session before.
- 26 Jun 2026+17.7%
- 25 Jun 2026+14.8%
- 21 May 2026-15.7%
Nothing announced by SLS that day or the session before.
- 20 May 2026+18.2%
Nothing announced by SLS that day or the session before.
Share of unusual movement by asset
For each asset, the share of SLS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | WT1 (Wilms Tumor-1 protein)Vaccine | Acute Myeloid LeukemiaMultiple Myeloma | |
| Phase 1/2 | CDK9Small molecule | Acute Myeloid Leukemia | |
| Phase 1 | GPNMBAntibody–drug conjugate | Non-Small Cell Lung CancerAcute Myeloid Leukemia |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $7.0M | $135M | $10M-$5.9M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $6.3M | $138M | $9.6M-$7.6M operating cash flow | report ↗ |
| 2026-Q1 | — | $5.1M | $107M | $8.4M-$8.8M operating cash flow | report ↗ |
| 2025-Q3 | — | $4.2M | $44M | $6.8M-$7.1M operating cash flow | report ↗ |
| 2025-Q2 | — | $3.9M | $25M | $6.6M-$7.3M operating cash flow | report ↗ |
| 2025-Q1 | — | $3.2M | $29M | $5.8M-$9.1M operating cash flow | report ↗ |
| 2024-Q3 | — | $4.4M | $21M | $7.1M-$7.8M operating cash flow | report ↗ |
| 2024-Q2 | — | $5.2M | $9.3M | $7.5M-$9.7M operating cash flow | report ↗ |
| 2024-Q1 | — | $5.1M | $19M | $9.6M-$11M operating cash flow | report ↗ |
| 2023-Q3 | $0 | $5.8M | $4.1M | $9.3M-$6.9M operating cash flow | report ↗ |
| 2023-Q2 | $0 | $5.9M | $14M | $8.8M-$7.6M operating cash flow | report ↗ |
| 2023-Q1 | $0 | $7.2M | $24M | $11M-$12M operating cash flow | report ↗ |
| 2022-Q3 | $0 | $4.3M | $21M | $7.0M-$5.8M operating cash flow | report ↗ |
| 2022-Q2 | $0 | $5.5M | $27M | $8.4M-$5.8M operating cash flow | report ↗ |
| 2022-Q1 | $1.0M | $4.6M | $14M | $17M-$7.2M operating cash flow | report ↗ |
| 2021-Q3 | $0 | $4.5M | $26M | $7.1M-$5.9M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $16M | $72M | $6.7M-$28M operating cash flow | report ↗ |
Sellas Life Sciences Group reported no disclosed revenue for fiscal year 2025. R&D spend was $16.02M, down 16.1% YoY, with cash and equivalents of $71.89M, a net loss of $26.86M, and quarterly net burn of $26.86M.
The filing focuses on clinical development rather than financial guidance. The Phase 3 REGAL trial of galinpepimut-S in AML maintenance continues, with 72 pooled events reported as of December 26, 2025 and final analysis planned at 80 events. The Phase 2 trial of SLS009 in relapsed/refractory AML met its primary endpoints, and FDA guidance supported advancement into a randomized 80-patient first-line study that began enrollment in Q1 2026. The company also entered an agreement with IMPACT-AML for European evaluation of SLS009 and remains in arbitration with 3D Medicines regarding milestone payments.
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-06-16 | Stergiou Angelos M. · director, President and CEO | Award / grant | 1,065,000 | — | — | Form 4 |
| 2026-01-07 | Wasman Jane · director | Award / grant | 50,000 | — | — | Form 4 |
| 2026-01-07 | Kalin Katherine Bach · director | Award / grant | 50,000 | — | — | Form 4 |
| 2026-01-07 | Burns John Thomas · CFO | Award / grant | 300,000 | — | — | Form 4 |
| 2026-01-07 | CICIC DRAGAN · SVP, Chief Development Officer | Award / grant | 300,000 | — | — | Form 4 |
| 2026-01-07 | SCHEINBERG DAVID A · director | Award / grant | 50,000 | — | — | Form 4 |
| 2026-01-07 | VAN NOSTRAND ROBERT L · director | Award / grant | 50,000 | — | — | Form 4 |
| 2026-01-07 | Varian John · director | Award / grant | 50,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 157 reporting institutions held 53.9M shares ($224.3M, 26.7% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 12,198,410 | $51.6M |
| 2 | STATE STREET CORP | 8,396,356 | $35.5M |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 7,525,929 | $31.8M |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 3,912,606 | $16.6M |
| 5 | MARSHALL WACE, LLP | 2,037,162 | $8.6M |
| 6 | JONES FINANCIAL COMPANIES LLLP | 1,675,077 | $7.3M |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1,462,806 | $6.2M |
| 8 | MORGAN STANLEY | 1,336,293 | $5.7M |
| 9 | NORTHERN TRUST CORP | 1,275,984 | $5.4M |
| 10 | VANGUARD FIDUCIARY TRUST CO | 1,202,839 | $5.1M |
| 11 | DAGCO, INC. | 1,028,780 | $4.4M |
| 12 | UBS Group AG | 745,419 | $3.2M |
| 13 | Invesco Ltd. | 698,080 | $3.0M |
| 14 | Nuveen, LLC | 670,974 | $2.8M |
| 15 | BANK OF AMERICA CORP /DE/ | 641,683 | $2.7M |